October, 2012

Therakind's Chief Executive, Dr Susan Conroy, is delighted to announce that Therakind has been awarded funding, through the Department of Health's Small Business Research Initiative (SBRI) Medicines Management competition, for the development of a simple novel device that enables rapid and easy treatment of hypoglycaemia.  Therakind was one of five pharmaceutical companies that were successful, out of a total of forty nine companies that submitted applications.

Dr Conroy said: “Severe hypoglycaemia currently results in at least 15,000 hospital admissions each year in England.  This funding gives us an excellent opportunity to provide long term benefits to people affected by the condition, as well as bring both quality and cost improvements to the NHS".